Skip to Main content Skip to Navigation
New interface
Journal articles

Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium

Claudia Pasqualini Jonathan Rubino Caroline Brard 1 Lydie Cassard Nicolas André 2 Windy Rondof Jean-Yves Scoazec Antonin Marchais Souad Nebchi 1 Lisa Boselli Jonathan Grivel Isabelle Aerts Estelle Thebaud Xavier Paoletti 1 Véronique Minard-Colin Gilles Vassal Birgit Geoerger 
1 CESP - Centre de recherche en épidémiologie et santé des populations
2 CRCM - Centre de Recherche en Cancérologie de Marseille
Document type :
Journal articles
Complete list of metadata
https://hal-amu.archives-ouvertes.fr/hal-03625350
Contributor : Nicolas André Connect in order to contact the contributor
Submitted on : Wednesday, March 30, 2022 - 6:29:25 PM
Last modification on : Friday, October 14, 2022 - 3:53:21 AM

Identifiers

Collections

CNRS | UNIV-AMU | UVSQ | UNIV-PARIS-SACLAY | CRCM | GS-SANTE-PUBLIQUE

Citation

Claudia Pasqualini, Jonathan Rubino, Caroline Brard, Lydie Cassard, Nicolas André, et al.. Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium. European Journal of Cancer, 2021, 150, pp.53-62. ⟨10.1016/j.ejca.2021.03.032⟩. ⟨hal-03625350⟩

Export

BibTeX TEI DC DCterms EndNote Datacite

Share

Metrics

Record views

21